Literature DB >> 26189575

Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas.

Bartlomiej Bartkowiak1, Christopher Yan1, Arno L Greenleaf2.   

Abstract

The RNA Polymerase II C-terminal domain (CTD) kinase CDK12 has been implicated as a tumor suppressor and regulator of DNA damage response genes. Although much has been learned about CDK12 and its activity, due to the lack of a specific inhibitor and the complications posed by long term RNAi depletion, much is still unknown about the particulars of CDK12 function. Therefore gaining a better understanding of CDK12's roles at the molecular level will be challenging without the development of additional tools. In order to address these issues we have used the CRISPR/Cas gene engineering system to create a mammalian cell line in which the only functional copy of CDK12 is selectively inhibitable by a cell-permeable adenine analog (analog-sensitive CDK12). Inhibition of CDK12 results in a perturbation of the phosphorylation patterns on the CTD and an arrest in cellular proliferation. This cell line should serve as a powerful tool for future studies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analog-sensitive; CDK12; CRISPR/Cas; CTD phosphorylation; Cell line; Unintended splice site

Mesh:

Substances:

Year:  2015        PMID: 26189575      PMCID: PMC4556607          DOI: 10.1016/j.bbagrm.2015.07.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

1.  Phosphorylation of RNA polymerase II is independent of P-TEFb in the C. elegans germline.

Authors:  Elizabeth Anne Bowman; Christopher Ray Bowman; Jeong H Ahn; William G Kelly
Journal:  Development       Date:  2013-07-31       Impact factor: 6.868

2.  Cyclin-dependent kinase 12 increases 3' end processing of growth factor-induced c-FOS transcripts.

Authors:  Tristan T Eifler; Wei Shao; Koen Bartholomeeusen; Koh Fujinaga; Stefanie Jäger; Jeff R Johnson; Zeping Luo; Nevan J Krogan; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2014-11-10       Impact factor: 4.272

3.  The regulation of glial-specific splicing of Neurexin IV requires HOW and Cdk12 activity.

Authors:  Floriano Rodrigues; Leila Thuma; Christian Klämbt
Journal:  Development       Date:  2012-03-29       Impact factor: 6.868

4.  Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7.

Authors:  Rob D Chapman; Martin Heidemann; Thomas K Albert; Reinhard Mailhammer; Andrew Flatley; Michael Meisterernst; Elisabeth Kremmer; Dirk Eick
Journal:  Science       Date:  2007-12-14       Impact factor: 47.728

Review 5.  Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription.

Authors:  Martin Heidemann; Corinna Hintermair; Kirsten Voß; Dirk Eick
Journal:  Biochim Biophys Acta       Date:  2012-09-07

6.  C-terminal repeat domain kinase I phosphorylates Ser2 and Ser5 of RNA polymerase II C-terminal domain repeats.

Authors:  Janice C Jones; Hemali P Phatnani; Timothy A Haystead; Justin A MacDonald; S Munir Alam; Arno L Greenleaf
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

7.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.

Authors:  Dalibor Blazek; Jiri Kohoutek; Koen Bartholomeeusen; Eric Johansen; Petra Hulinkova; Zeping Luo; Peter Cimermancic; Jernej Ule; B Matija Peterlin
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

8.  Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.

Authors:  Kingsley M Ekumi; Hana Paculova; Tina Lenasi; Vendula Pospichalova; Christian A Bösken; Jana Rybarikova; Vitezslav Bryja; Matthias Geyer; Dalibor Blazek; Matjaz Barboric
Journal:  Nucleic Acids Res       Date:  2015-02-20       Impact factor: 16.971

9.  Updating the CTD Story: From Tail to Epic.

Authors:  Bartlomiej Bartkowiak; April L Mackellar; Arno L Greenleaf
Journal:  Genet Res Int       Date:  2011-10-15

10.  3' end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells.

Authors:  Lee Davidson; Lisa Muniz; Steven West
Journal:  Genes Dev       Date:  2014-01-29       Impact factor: 11.361

View more
  21 in total

1.  CDK regulation of transcription by RNAP II: Not over 'til it's over?

Authors:  Robert P Fisher
Journal:  Transcription       Date:  2016-12-22

Review 2.  The pol II CTD: new twists in the tail.

Authors:  Justyna Zaborowska; Sylvain Egloff; Shona Murphy
Journal:  Nat Struct Mol Biol       Date:  2016-09-06       Impact factor: 15.369

Review 3.  Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.

Authors:  Arno L Greenleaf
Journal:  Transcription       Date:  2018-10-22

Review 4.  Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.

Authors:  Pabitra K Parua; Robert P Fisher
Journal:  Nat Chem Biol       Date:  2020-06-22       Impact factor: 15.040

5.  Allele-Specific Inhibition of Histone Demethylases.

Authors:  Shana Wagner; Megan Waldman; Simran Arora; Sinan Wang; Valerie Scott; Kabirul Islam
Journal:  Chembiochem       Date:  2019-03-14       Impact factor: 3.164

6.  Rapid block of pre-mRNA splicing by chemical inhibition of analog-sensitive CRK9 in Trypanosoma brucei.

Authors:  Ujwala Gosavi; Ankita Srivastava; Nitika Badjatia; Arthur Günzl
Journal:  Mol Microbiol       Date:  2020-03-04       Impact factor: 3.501

Review 7.  The Bump-and-Hole Tactic: Expanding the Scope of Chemical Genetics.

Authors:  Kabirul Islam
Journal:  Cell Chem Biol       Date:  2018-08-02       Impact factor: 8.116

8.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

9.  Taking Aim at Glycolysis with CDK8 Inhibitors.

Authors:  Robert P Fisher
Journal:  Trends Endocrinol Metab       Date:  2018-02-20       Impact factor: 12.015

Review 10.  Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Authors:  Steven R Whittaker; Aurélie Mallinger; Paul Workman; Paul A Clarke
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.